A significant reduction of tumor growth was observed at this dose level (tumor size at the end of study +/− SEM per group in mm3: PBS 771 ± 10, anti-CSPG4-(PDD) 88 ± 28, isotype-(PDD) 770 ± 11, PDD alone 791 ± 18, anti-CSPG4 + PDD 787 ± 12) (p < 0.0001, Dunnett’s multiple comparisons test) (Figure 6A, left panel), and below the Maximum Tolerated Dose (MTD) (Figure S3). The gene discussed is CSPG4; the disease is neoplasm.